A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF

See also
Status	Clinical Trial	Phase
Terminated	`NCT01141478` - Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria	N/A
Recruiting	`NCT05580835` - PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma	N/A
Active, not recruiting	`NCT05389527` - Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT04560751` - TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Withdrawn	`NCT02939807` - A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma	Phase 2
Completed	`NCT01915602` - Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)	Phase 2
Completed	`NCT04970212` - Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Recruiting	`NCT02403544` - Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma	Phase 1
Completed	`NCT01897038` - A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma	Phase 1
Terminated	`NCT01337492` - Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)	Phase 0
Completed	`NCT01012011` - Regulatory Post Marketing Surveillance Study on Nexavar®	N/A
Completed	`NCT01003015` - Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma	Phase 2
Terminated	`NCT01020812` - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma	Phase 1/Phase 2
Completed	`NCT00559455` - Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT00384800` - A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)	Phase 2
Terminated	`NCT00582400` - A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver	Phase 2
Completed	`NCT00056992` - Testing of ADI-PEG in Hepatocellular Carcinoma	Phase 2
Completed	`NCT02859324` - A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)	Phase 1/Phase 2
Terminated	`NCT02439008` - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response	N/A
Completed	`NCT01915589` - Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)	Phase 2

NCT number	NCT03289533
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 1
Start date	September 8, 2017
Completion date	October 25, 2019

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms